PSMA PET/CT scan for liver cancer (HCC)
Part of Cancer, Digestive system clinical trials.
This study tests a new type of PET/CT scan (called PSMA) that may help doctors see liver cancer (HCC) better. The scan takes detailed images to track how the cancer behaves, which could help choose the best treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of hepatocellular carcinoma (HCC, a type of liver cancer) that is either confirmed by biopsy or seen on scans (CT/MRI), or you need a new scan to check if the cancer has come back or spread.
- You must have at least one tumor that can be seen on a CT or MRI scan.
- You must be well enough to do daily activities (like walking and dressing) – this is called ECOG 0-2.
- Your liver function must be good (Child-Pugh A, determined by blood tests).
- You must not have serious heart disease, uncontrolled illnesses, or have had certain treatments (like radioembolization) in the last 3 months.
- You must not be pregnant or breastfeeding, and must agree to use two forms of contraception for several months after the scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a special PET scan (PSMA PET) can better stage liver cancer that has not been treated yet and is at a moderate to advanced stage (BCLC B or C). It may help guide treatment decisions.
This study tests a new type of imaging scan (called 68Ga-NYM207 PET/CT) that may help doctors better find and understand liver cancer. You would receive the scan once to see if it helps doctors plan your treatment or monitor your cancer.
This study uses a special PET/MRI scan with a tracer called PSMA-11 to look at how liver cirrhosis affects the liver. It may help doctors better understand and monitor the disease.
This study uses two different PSMA PET/CT tracers to see how well they detect cancer in patients with advanced prostate cancer that has spread or stopped responding to hormone therapy. The goal is to improve imaging for better treatment decisions.
This Phase 2 study tests an imaging scan called 18F-PSMA PET/CT to find tumors that have a specific marker (PSMA). It may help doctors better locate and evaluate PSMA-positive cancers.
This trial uses a special PET scan that targets a protein found in liver cancer cells. It aims to see if this new scan works better than an enhanced MRI to find liver cancer. If you have suspected or confirmed liver cancer, this study might help guide your care.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.